Calypso Biotech

Photo of three hands placing together three white puzzle pieces
Biotech

Novartis dances into JPM with $250M Calypso buyout, 2 more deals

Novartis is paying $250 million to renew its interest in a cytokine and dropping $185 million on two RNAi cardiovascular disease candidates.
Nick Paul Taylor Jan 8, 2024 6:28am
Fountain on Lake Geneva

Merck KGaA spinoff licenses IBD drug to Eisai joint venture

Mar 31, 2017 4:25am